CN1699383A - 新的芳基果糖－1,6－二磷酸酶抑制剂 - Google Patents

新的芳基果糖－1,6－二磷酸酶抑制剂 Download PDF

Info

Publication number
CN1699383A
CN1699383A CNA2005100720821A CN200510072082A CN1699383A CN 1699383 A CN1699383 A CN 1699383A CN A2005100720821 A CNA2005100720821 A CN A2005100720821A CN 200510072082 A CN200510072082 A CN 200510072082A CN 1699383 A CN1699383 A CN 1699383A
Authority
CN
China
Prior art keywords
aryl
group
replacement
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005100720821A
Other languages
English (en)
Chinese (zh)
Inventor
B·C·波克赛尔
党群
K·R·雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of CN1699383A publication Critical patent/CN1699383A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005100720821A 2000-03-08 2001-03-07 新的芳基果糖－1,6－二磷酸酶抑制剂 Pending CN1699383A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18775000P 2000-03-08 2000-03-08
US60/187,750 2000-03-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA018090214A Division CN1516705A (zh) 2000-03-08 2001-03-07 新的芳基果糖-1,6-二磷酸酶抑制剂

Publications (1)

Publication Number Publication Date
CN1699383A true CN1699383A (zh) 2005-11-23

Family

ID=22690309

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005100720821A Pending CN1699383A (zh) 2000-03-08 2001-03-07 新的芳基果糖－1,6－二磷酸酶抑制剂
CNA018090214A Pending CN1516705A (zh) 2000-03-08 2001-03-07 新的芳基果糖-1,6-二磷酸酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA018090214A Pending CN1516705A (zh) 2000-03-08 2001-03-07 新的芳基果糖-1,6-二磷酸酶抑制剂

Country Status (20)

Country Link
US (2) US6919322B2 (enExample)
EP (2) EP1607401A1 (enExample)
JP (1) JP2003525944A (enExample)
KR (1) KR20020079988A (enExample)
CN (2) CN1699383A (enExample)
AT (1) ATE350385T1 (enExample)
AU (2) AU2001245532B2 (enExample)
BR (1) BR0109062A (enExample)
CA (1) CA2401706A1 (enExample)
CZ (1) CZ20023018A3 (enExample)
DE (1) DE60125734T2 (enExample)
HU (1) HUP0300344A3 (enExample)
IL (2) IL151248A0 (enExample)
MX (1) MXPA02008722A (enExample)
NO (1) NO20024240L (enExample)
PL (1) PL357251A1 (enExample)
RU (1) RU2002126616A (enExample)
SK (1) SK12722002A3 (enExample)
WO (1) WO2001066553A2 (enExample)
ZA (1) ZA200207004B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111116647A (zh) * 2019-12-02 2020-05-08 西安电子科技大学 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
CZ297264B6 (cs) * 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
CN1740182A (zh) * 1999-12-22 2006-03-01 症变治疗公司 新的双氨基化膦酸酯前药
EP1607401A1 (en) 2000-03-08 2005-12-21 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-Bisphosphatase inhibitors
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1535630A1 (en) * 2002-07-23 2005-06-01 Sankyo Company, Limited Preventive for the onset of diabetes
FR2846327B1 (fr) * 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
EP1778250A2 (en) * 2004-08-18 2007-05-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
BRPI0519006A2 (pt) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos
CN101115483A (zh) * 2004-12-15 2008-01-30 第一三共株式会社 含有FBPase抑制剂的药物组合物
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
CA2695583A1 (en) 2007-08-13 2009-02-19 Metabasis Therapeutics, Inc. Novel activators of glucokinase
EP2058308A1 (fr) 2007-11-12 2009-05-13 Merck Sante Dérivés de benzimidazoledihydrothiadiazinone comme inhibiteurs de fructose-1,6-biphosphatase et compositions pharmaceutiques les contenant.
EP2408774B1 (en) 2009-03-20 2014-11-26 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
US9006568B2 (en) * 2012-02-15 2015-04-14 Phillips 66 Company Synthesis of photovoltaic conjugated polymers
KR102062517B1 (ko) * 2012-04-20 2020-01-06 바이엘 크롭사이언스 악티엔게젤샤프트 Ｎ-시클로알킬-ｎ-［（헤테로시클릴페닐）메틸렌］-（티오）카르복사미드 유도체
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9691986B2 (en) 2012-12-03 2017-06-27 Solarmer Energy, Inc. Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
US9911919B2 (en) 2015-10-01 2018-03-06 Phillips 66 Company Process of manufacturing an electron transport material
US10312448B2 (en) 2015-10-01 2019-06-04 Phillips 66 Company Process of manufacturing an electron transport material
WO2017058406A1 (en) 2015-10-01 2017-04-06 Phillips 66 Company Formation of films for organic photovoltaics
US10418555B2 (en) 2015-10-01 2019-09-17 Phillips 66 Company Formation of films for organic photovoltaics
US9905769B2 (en) 2015-10-01 2018-02-27 Phillips 66 Company Process of manufacturing an electron transport material
CN109715637B (zh) 2016-07-22 2022-04-05 百时美施贵宝公司 葡萄糖激酶激活剂及其使用方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL72851C (enExample) * 1950-10-31 1900-01-01
US2683168A (en) * 1950-12-22 1954-07-06 California Research Corp Preparation of organo phosphonyl chlorides
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
GB2043073B (en) * 1979-02-13 1983-05-11 Symphar Sa Mono-and diphosphonate compounds
US4640701A (en) * 1984-04-17 1987-02-03 Ciba-Geigy Corporation Herbicidal phosphonic acid and phosphinic acid derivatives
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0243173B1 (en) * 1986-04-24 1991-06-26 Fujisawa Pharmaceutical Co., Ltd. New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5045557A (en) * 1987-03-20 1991-09-03 Schering Agrochemicals Ltd. Imidazable fungicides and use thereof
US4968790A (en) 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
JPH03504728A (ja) 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ，インコーポレイテッド Ａｉｃａリボシドの放出および血液グルコースの低減のための化合物および方法
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5208235A (en) * 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole derivatives
US5278153A (en) * 1992-05-18 1994-01-11 E. R. Squibb & Sons, Inc. Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
DE69426904T2 (de) 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
ATE486882T1 (de) 1993-09-17 2010-11-15 Gilead Sciences Inc Nukleotidanaloge
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2322487C (en) 1998-03-06 2010-07-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
EP1070084A4 (en) 1998-03-16 2001-09-12 Ontogen Corp PIPERAZINE AS INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE)
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
DE19843383A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
WO2000038666A2 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
SK12442001A3 (sk) * 1999-03-05 2002-06-04 Metabasis Therapeutics, Inc. Cyklické fosforamidáty, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú
CN1740182A (zh) * 1999-12-22 2006-03-01 症变治疗公司 新的双氨基化膦酸酯前药
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
EP1607401A1 (en) 2000-03-08 2005-12-21 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-Bisphosphatase inhibitors
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CN101301294A (zh) 2000-07-06 2008-11-12 症变治疗公司 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
EP1778250A2 (en) 2004-08-18 2007-05-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111116647A (zh) * 2019-12-02 2020-05-08 西安电子科技大学 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途
CN111116647B (zh) * 2019-12-02 2021-08-24 西安电子科技大学 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途

Also Published As

Publication number Publication date
WO2001066553A3 (en) 2002-03-14
WO2001066553A2 (en) 2001-09-13
US20020040014A1 (en) 2002-04-04
US6919322B2 (en) 2005-07-19
DE60125734D1 (en) 2007-02-15
DE60125734T2 (de) 2007-10-25
IL151248A (en) 2007-06-17
JP2003525944A (ja) 2003-09-02
RU2002126616A (ru) 2004-03-20
MXPA02008722A (es) 2004-05-05
ATE350385T1 (de) 2007-01-15
CN1516705A (zh) 2004-07-28
EP1265907B9 (en) 2007-05-09
EP1265907B1 (en) 2007-01-03
HK1051865A1 (en) 2003-08-22
EP1607401A1 (en) 2005-12-21
NO20024240D0 (no) 2002-09-05
US20050176684A1 (en) 2005-08-11
IL151248A0 (en) 2003-04-10
HUP0300344A2 (hu) 2003-06-28
AU2001245532B2 (en) 2005-08-11
SK12722002A3 (sk) 2003-04-01
US7371739B2 (en) 2008-05-13
ZA200207004B (en) 2003-12-01
CZ20023018A3 (cs) 2003-01-15
KR20020079988A (ko) 2002-10-21
BR0109062A (pt) 2002-11-26
CA2401706A1 (en) 2001-09-13
NO20024240L (no) 2002-11-08
PL357251A1 (en) 2004-07-26
AU4553201A (en) 2001-09-17
HUP0300344A3 (en) 2007-05-29
EP1265907A2 (en) 2002-12-18

Similar Documents

Publication Publication Date Title
CN1326459A (zh) 新的果糖1,6－二磷酸酶的杂芳族抑制剂
CN1740182A (zh) 新的双氨基化膦酸酯前药
CN1516705A (zh) 新的芳基果糖-1,6-二磷酸酶抑制剂
CN1054850C (zh) 用于治疗的哌嗪化合物
CN1350466A (zh) 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
CN1656109A (zh) 非核苷逆转录酶抑制剂
CN1296485A (zh) 取代的吲哚链烷酸
CN1190401A (zh) C－4′修饰的腺苷激酶抑制剂
CN1660840A (zh) 治疗炎性疾病的酞嗪衍生物
CN1639135A (zh) N－芳基－2－噁唑烷酮－5－酰胺及其衍生物和它们作为抗菌剂的用途
CN1066150C (zh) 作为基质金属蛋白酶抑制剂的桥式吲哚
CN1207100A (zh) 新型吲哚－2,3－二酮－3－肟衍生物
CN1085907A (zh) 新的硫取代含氮杂环膦酸化合物，药物组合物，和治疗钙与磷酸盐异常代谢的方法
CN1265660A (zh) 2－(4－芳基或杂芳基－哌嗪－1－基甲基)－1h－吲哚衍生物
CN1934093A (zh) 嘧啶基膦酸酯抗病毒化合物和使用方法
CN1042031C (zh) 含季氮的膦酸化合物、药物组合物及其应用
CN1061049C (zh) 含硫的膦酸化合物，药物组合物及其在制药方面的用途
CN1489596A (zh) α-取代的β-氨基乙基膦酸酯类化合物
CN1832950A (zh) 丝氨酸蛋白酶抑制剂的含哌嗪膦酸化合物
CN1704423A (zh) 新的果糖1,6－二磷酸酶的杂芳族抑制剂
CN1021050C (zh) 丁烯酰胺衍生物的制备方法
CN1604904A (zh) 作为丝氨酸蛋白酶抑制剂的膦酸化合物
CN1061594A (zh) 作为白细胞三烯拮抗药的羟烷基喹啉醚酸
CN1044912C (zh) 硫取代环状膦酸盐化合物及其药物组合物和用途
CN1087640A (zh) 新型膦酰基磺酸酯化合物，药物组合物，以及治疗反常钙和磷酸盐代谢的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication